Abiopharma

🔍 Wilterding Mark (Executive)

Company: RxSight, Inc. (RXST)

Report Date: 2026-08-31

Detailed Transactions and Holdings:

• Acquired 20,441 shares of Common Stock (Direct)
  Date: 2026-08-31 | Code: M | equity_swap_involved: false | shares_owned_after: 32,814.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 7,765 shares of Common Stock at $6.96 per share (Direct)
  Date: 2026-09-02 | Code: S | equity_swap_involved: false | shares_owned_after: 25,049.00 | transaction_form_type: 4 | Footnotes: F2
• Sold 20,441 shares of Restricted Stock Unit (Derivative)
  Date: 2026-08-31 | Code: M | equity_swap_involved: false | shares_owned_after: 122,646.00 | transaction_form_type: 4 | Footnotes: F1, F3, F3

Footnotes:

• F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
• F2: Represents the number of shares sold to cover the tax withholding obligations in connection with the vesting of RSUs and does not represent a discretionary sale by the Reporting Person.
• F3: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, one eighth (1/8th) of the shares subject to the RSU award vested on February 28, 2026, and one eighth (1/8th) of the shares subject to the RSU award will vest every six months thereafter on the last day of February and the last day of August over a four-year period.